Abstract
Objective: Levosimendan in a new inodilator drug that sensitises troponin C in heart muscle cells to calcium, thus improving contractility. In previous studies, a single 2 mg intravenous dose of levosimendan increased cardiac output (CO) in healthy volunteers by about 40% and decreased pulmonary capillary wedge pressure in heart failure patients by 40–50%.
The aim of the present, double-blind study was to evaluate the safety of concomitant use of levosimendan and an ACE-inhibiting drug.
Methods: The haemodynamic effects of levosimendan, given with or without captopril, were evaluated by using 2-dimensional echocardiography, repeated blood pressure measurements and by ambulatory ECG recordings. Twenty-four male patients with stable NYHA II-III heart failure (EF<40%) after a previous myocardial infarct were given, in randomised order, a single IV infusion of levosimendan or placebo. The infusions were repeated after 2 weeks treatment with upto 50 mg b.i.d. of captopril. Twelve patients received levosimendan 1 mg and twelve received 2 mg.
Results: Mean CO was increased from 6.0 to 6.81·min−1 in patients receiving 1 mg levosimendan compared to placebo, but only from 6.3 to 6.51·min−1 in patients receiving 2 mg. The increase in CO was statistically significant when all levosimendan patients were compared to placebo. Heart rate did not change after either dose. Mean stroke volume increased significantly after 1 mg but not after 2 mg of levosimendan. The addition of captopril did not change the effects of levosimendan. No additional decrease in systolic or diastolic blood pressure was observed when levosimendan and captopril were given concomitantly.
Conclusion: It seems that concomitant treatment with captopril does not change the haemodynamic effects of levosimendan. No adverse haemodynamic interactions were seen.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Rügg JC (1987) Dependence of cardiac contractility on myofibrillar calcium sensitivity. N Physiol Sci 2:179–182
Smith SJ, England PJ (1990) The effects of reported Ca2+ sensitizers on the rates of Ca2+ release from cardiac troponin C and the troponin-tropomyosin complex. Br J Pharmacol 11:779–785
Haikala H, Lindén IB (1995) Mechanism of action of calcium sensitizing drugs. J Cardiovasc Pharmacol 26 [Suppl 1]:10–19
Hagemeijer F, Brand HJ, van Mechelen R (1989) Hemodynamic effects of pimobendan given orally in congestive heart failure secondary to ischemic or idiopathic cardiomyopathy. Am J Cardiol 63:571–576
Mori M, Takeuchi M, Takaoka H, Hata K, Yamakawa H, Yokoyama M (1994) Unique vasorelaxing properties with a new cardiotonic agent MCl-154, in human diseased heart. Comparison with phosphodiesterase inhibitor. Abstract. JACC 1:479
Lilleberg J, Sundberg S, Nieminen MS (1995) Dose-ranging study of a new calcium sensitizer, levosimendan, in patients with left ventricular dysfunction. J Cardiovasc Pharmacol 26 [Suppl 1]:63–69
Pollesello P, Ovaska M, Kaivola J, Tilgman C, Lundström K, Kalkkinen N, et al. (1994) Binding of a new Ca2+ sensitizer, levosimendan, to recombinant human cardiac troponin C. A molecular modelling, fluorescence probe and proton nuclear magnetic resonance study. J Biol Chem 269:28584–28590
Lilleberg J, Sundberg S, Häyhä M, Akkila J, Nieminen MS (1994) Haemodynamic dose-efficacy of levosimendan in healthy volunteers. Eur J Clin Pharmacol 47:267–274
Lilleberg J, Antila S, Karlsson M, Nieminen Markku S, Pentikäinen P (1994) Pharmacokinetics and pharmacodynamics of simendan, a novel calcium sensitizer, in healthy volunteers. CPT 56: 554–563
Sandell E-P, Häyhä M, Antila S, Heikkinen P, Ottoila P, Lehtonen LA, Pentikäinen PJ (1995) Pharmacokinetics of levosimendan in healthy volunteers and in patients with heart failure. J Cardiovasc Pharmacol 26 [Suppl 1]:57–62
Packer M, Carver JR, Rodeheffer RJ, Ivanhoe RJ, DiBianco R, Zeldis SM, et al. (1991) Effect of oral milinone on mortality in severe chronic heart failure. The PROMISE Study Research Group. N Engl J Med 325 (21):1468–1475
Cowley AJ, Skene AM, Enoximone Investigators et al. (1994) Treatment of severe heart failure: quantity or quality of life? A trial with enoximone. Br Heart J 72:226–230
Feldman AM, Bristow MR, Parmley WW, Carson PE, Pepine CJ, Gilbert EM, et al. (1993) Effects of vesnarinone on MORBIDITY and mortality in patients with heart failure. Vesnarinone Study Group. N Engl J Med 329:149–155
Edes I, Csanady M, Papp J (1993) The effects of new calcium sensitizers (levosimendan, pimobendan and EMD 53998) on myocardial protein phosphorylation. Abstract. Eur Heart J 14 [Suppl]:198
Pfeffer MA, Braunwald E, Moye LA et al. (1992) Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 327: 669–677
Vannan MA, Taylor DJE, Webb-Peloe MM, Konstam MA (1993) ACE inhibitors after myocardial infarction. Br Med J 306:531–532
Packer M, Medina N, Yushak M, Meller J (1983) Hemodynamic patterns of response during long-term captopril therapy for severe chronic heart failure. Circulation 68:803–812
Beerman B, Nyquist O, Höglund C, Jacobson K-A, Näslund U, Jensen-Urstad M (1993) Acute hemodynamic effects and pharmacokinetics of ramipril in patients with heart failure. Eur J Clin Pharmacol 45:241–246
Lehtonen L, Mills-Owens P, Akkila J (1995) Safety of levosimendan and other calcium sensitizers. J Cardiovasc Pharmacol 26 [Suppl 1]:70–76
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Antila, S., Lehtonen, L., Sandell, EP. et al. Haemodynamic interactions of a new calcium sensitizing drug levosimendan and captopril. Eur J Clin Pharmacol 49, 451–458 (1996). https://doi.org/10.1007/BF00195930
Received:
Accepted:
Issue Date:
DOI: https://doi.org/10.1007/BF00195930